Two Sigma Advisers LP Sells 3,900 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Two Sigma Advisers LP decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 61,900 shares of the medical equipment provider's stock after selling 3,900 shares during the period. Two Sigma Advisers LP's holdings in Zimmer Biomet were worth $6,538,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Franklin Resources Inc. lifted its position in Zimmer Biomet by 398.7% in the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after acquiring an additional 2,796,372 shares in the last quarter. Norges Bank bought a new position in Zimmer Biomet during the fourth quarter worth about $216,223,000. Dodge & Cox increased its stake in Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after acquiring an additional 2,044,645 shares during the period. Nuveen Asset Management LLC grew its position in Zimmer Biomet by 191.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider's stock worth $146,763,000 after acquiring an additional 913,310 shares during the last quarter. Finally, Sound Shore Management Inc. CT bought a new stake in Zimmer Biomet during the 4th quarter worth approximately $81,447,000. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

NYSE ZBH traded down $0.24 during mid-day trading on Thursday, hitting $92.06. The stock had a trading volume of 497,090 shares, compared to its average volume of 1,793,934. The company has a 50 day simple moving average of $100.72 and a 200 day simple moving average of $105.04. The company has a market cap of $18.21 billion, a price-to-earnings ratio of 20.69, a P/E/G ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.92 and a 52-week high of $116.86. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm's revenue for the quarter was up 1.1% on a year-over-year basis. During the same period last year, the business posted $1.94 earnings per share. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Stifel Nicolaus set a $115.00 price target on Zimmer Biomet and gave the stock a "buy" rating in a report on Tuesday, May 6th. The Goldman Sachs Group lowered their target price on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Royal Bank of Canada reduced their target price on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Finally, Morgan Stanley decreased their price objective on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus target price of $111.53.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.